Skip to content
The Realist Juggernaut

The Realist Juggernaut

There's a Powerful Force in Realism

WHO OWNS YOUR DNA NOW? Regeneron Buys 23andMe in $256 Million Deal Amid Mounting Fears Over Genetic Privacy

Posted on May 22, 2025 By John Neff No Comments on WHO OWNS YOUR DNA NOW? Regeneron Buys 23andMe in $256 Million Deal Amid Mounting Fears Over Genetic Privacy
INDEPENDENT VOICES GROW THROUGH SUPPORT  •  MEET OUR SPONSORS IN OUR TRJ AD'S SECTION AT THE BOTTOM  •  INDEPENDENT VOICES GROW THROUGH SUPPORT  •  MEET OUR SPONSORS IN OUR TRJ AD'S SECTION AT THE BOTTOM  •  INDEPENDENT VOICES GROW THROUGH SUPPORT  •  MEET OUR SPONSORS IN OUR TRJ AD'S SECTION AT THE BOTTOM  • 
INDEPENDENT VOICES GROW THROUGH SUPPORT  •  MEET OUR SPONSORS IN OUR TRJ AD'S SECTION AT THE BOTTOM  •  INDEPENDENT VOICES GROW THROUGH SUPPORT  •  MEET OUR SPONSORS IN OUR TRJ AD'S SECTION AT THE BOTTOM  •  INDEPENDENT VOICES GROW THROUGH SUPPORT  •  MEET OUR SPONSORS IN OUR TRJ AD'S SECTION AT THE BOTTOM  • 
Listen to This Article
Ready
0%

Thank you for reading or listening to The Realist Juggernaut. Independent journalism should be accessible to everyone.

Article Bookmark
0%
Move through the article or mark your place.
Day
00
–:–
Post Activated
Scroll down to press Like

Category: Biotech Acquisition / Genetic Data Ethics
Buyer: Regeneron Pharmaceuticals
Seller: 23andMe Inc. (bankruptcy status confirmed)
Transaction Value: $256 Million
Assets Acquired:

  • Total Health and Research Services
  • Personal Genome Service
  • Consumer DNA Testing Infrastructure
  • Proprietary Biobank and Genomic Dataset
    Deal Status: Pending Final Court Review (Privacy Ombudsman Report Due June 10, 2025)

FROM FAMILY TREES TO PHARMA FILES

Once hailed as a Silicon Valley success story redefining consumer genetics, 23andMe has now been acquired by pharmaceutical giant Regeneron for $256 million — a price tag that raises eyebrows not for its size, but for what it includes: the genetic blueprints of millions of Americans.

The acquisition follows 23andMe’s March 2025 bankruptcy filing, an event that triggered a flood of panic among privacy experts, consumers, and legal analysts. At the heart of the concern? The question no one really wants to ask:

What happens to your DNA when the company that stored it no longer exists?

Now, that question has an answer. And it’s one that may change the rules of genetic privacy forever.


THE BIOTECH TRANSFER: WHAT’S REALLY BEING SOLD

Regeneron isn’t just buying a struggling company. It’s acquiring:

  • One of the world’s largest privately held genetic biobanks
  • Access to longitudinal consumer DNA records tied to names, ancestry, health traits, and behavior
  • Infrastructure to run direct-to-consumer genome testing
  • Research pipelines built on predictive health algorithms trained on real genetic samples

While the company insists that it will respect 23andMe’s existing privacy policy, that assurance has done little to ease public concern — especially as the scope of what was acquired includes not just anonymized datasets but infrastructure capable of linking genetic records to identifiable individuals.


THE PROMISE OF “NO SHARING” — UNTIL IT’S TOO LATE

23andMe’s privacy policy currently prohibits sharing genetic information with:

  • Insurers
  • Employers
  • Law enforcement (without a warrant or court order)
  • Public databases

It also allows users to request deletion of their data at any time — a feature that was heavily used following the bankruptcy announcement, with a surge in deletion requests spurred by warnings from figures like California Attorney General Rob Bonta.

But here’s the dilemma: Once data is copied, extracted, or studied, deletion is not retroactive.

“23andMe consumers could not have envisioned, or meaningfully consented to, their genetic data being sold or used for purposes outside of the original context to discover family heritage or genealogy,” said Suzanne Bernstein of the Electronic Privacy Information Center.


FTC, LAWMAKERS, AND WATCHDOGS SOUND THE ALARM

Following news of the acquisition, Federal Trade Commission Chair Andrew Ferguson declared that no buyer may retroactively alter 23andMe’s existing privacy framework. The agency has warned that any deviation could trigger federal enforcement or antitrust scrutiny.

But even with FTC oversight, privacy advocates remain skeptical — especially given the industry’s track record of quiet policy amendments, opaque data sharing, and ethically ambiguous research partnerships.

23andMe, under fire, claims it required all bidders in the bankruptcy process to legally agree to uphold the privacy policy. A court-appointed ombudsman has been tasked with reviewing the full implications of the sale, with a final report expected by June 10, 2025.


REGNERON’S INTEREST: MEDICINE… OR MARKETPLACE?

Regeneron’s statement about the acquisition frames the move as a healthcare opportunity, not a surveillance operation. The company’s Senior VP Aris Baras emphasized:

“We assure 23andMe customers that we are committed to protecting the dataset with our high standards of data privacy, security, and ethical oversight.”

But critics point out the obvious: Regeneron is not a data vault. It’s a pharmaceutical company. And that means its business model relies on targeted therapeutics, genomic research, and predictive health analytics — all of which benefit enormously from the type of long-range, population-scale genetic data 23andMe has spent over a decade collecting.

Add to this the value of machine learning models trained on this genomic dataset, and the acquisition begins to look less like a bailout and more like a strategic biotech asset grab.


THE FALLOUT: PRIVACY ISN’T JUST A SETTING — IT’S A PHILOSOPHY

This deal lands at a dangerous intersection:

  • A bankrupt data-rich company
  • A healthcare behemoth seeking expansion
  • Weak federal genetic privacy protections
  • Growing consumer mistrust

And in the middle? The most intimate identifier we possess: our DNA.

As Suzanne Bernstein of EPIC warned, without strong consumer data protections, even pledges of compliance mean little. In an era where biometric data, family trees, and predictive disease profiles are monetized at scale, consumers are often the last to know — and the least protected.


THE UNSEEN RISK: THE NEXT DATA GOLD RUSH

Beyond privacy, the deeper threat is future scope creep:

  • What happens when a pharmaceutical company uses this dataset to model who gets sick — and what they’ll pay to stay healthy?
  • What if insurers gain access indirectly through affiliated platforms, anonymized tags, or marketing partners?
  • Could this data one day guide healthcare premiums, job screenings, or AI-driven life expectancy scoring?

These aren’t science fiction questions. They are foreseeable outcomes in a system that increasingly views genetic data as market leverage, not sacred trust.



image: 23&ME


🔥 NOW AVAILABLE! 🔥

📖 INK & FIRE: BOOK 1 📖

A bold and unapologetic collection of poetry that ignites the soul. Ink & Fire dives deep into raw emotions, truth, and the human experience—unfiltered and untamed.

🔥 Kindle Edition 👉 https://a.co/d/9EoGKzh
🔥 Paperback 👉 https://a.co/d/9EoGKzh
🔥 Hardcover Edition 👉 https://a.co/d/0ITmDIB

Get your copy today and experience poetry like never before. #InkAndFire #PoetryUnleashed #FuelTheFire

🚨 NOW AVAILABLE! 🚨

📖 THE INEVITABLE: THE DAWN OF A NEW ERA 📖

A powerful, eye-opening read that challenges the status quo and explores the future unfolding before us. Dive into a journey of truth, change, and the forces shaping our world.

🔥 Kindle Edition 👉 https://a.co/d/0FzX6MH
🔥 Paperback 👉 https://a.co/d/2IsxLof
🔥 Hardcover Edition 👉 https://a.co/d/bz01raP

Get your copy today and be part of the new era. #TheInevitable #TruthUnveiled #NewEra

🚀 NOW AVAILABLE! 🚀
📖 THE FORGOTTEN OUTPOST 📖
The Cold War Moon Base They Swore Never Existed

What if the moon landing was just the cover story?

Dive into the boldest investigation The Realist Juggernaut has ever published—featuring declassified files, ghost missions, whistleblower testimony, and black-budget secrets buried in lunar dust.

🔥 Kindle Edition 👉 https://a.co/d/2Mu03Iu
🛸 Paperback Coming Soon

Discover the base they never wanted you to find. TheForgottenOutpost #RealistJuggernaut #MoonBaseTruth #ColdWarSecrets #Declassified



Support truth, health, and preparedness by shopping the Alex Jones Store through our link. Every purchase helps sustain independent voices and earns us a 10% share to fuel our mission. Shop now and make a difference!

https://thealexjonesstore.com?sca_ref=7730615.EU54Mw6oyLATer7a



Back to Blog
TRJ ADVERTISING NOTICE  •  Businesses and organizations purchasing advertising space on The Realist Juggernaut are independent advertisers. Advertising placement does not constitute affiliation, partnership, sponsorship, or endorsement by The Realist Juggernaut.  •  TRJ ADVERTISING NOTICE  •  Businesses and organizations purchasing advertising space on The Realist Juggernaut are independent advertisers. Advertising placement does not constitute affiliation, partnership, sponsorship, or endorsement by The Realist Juggernaut.  • 

Sponsored • TRJ Ads
Inquiries: contact@therealistjuggernaut.com

AD 1
AD 2
AD 3
AD 4
AD 5
AD 6
AD 7
AD 8
AD 9
AD 10
AD 11
AD 12
AD 13
AD 14
AD 15
AD 16
AD 17
AD 18
AD 19
AD 20

Like this:

Like Loading…
⚠ THE ANSWER TO 1984 IS 1776 • AI IS THE ACCELERATOR: MORE AI MEANS MORE OPTIMIZATION, MORE OPTIMIZATION MEANS MORE MONEY AND CONTROL, AND MONEY PLUS CONTROL HELPS ENTRENCH POWER • 1984 WAS THE WARNING • 1776 IS THE RESPONSE • WE ARE NOT YOUR DATA • WE ARE NOT YOUR PATTERN • WE ARE NOT AGAINST AI - JUST THOSE WHO WANT CONTROL • WE ARE FREE ⚠
⚠ THE ANSWER TO 1984 IS 1776 • AI IS THE ACCELERATOR: MORE AI MEANS MORE OPTIMIZATION, MORE OPTIMIZATION MEANS MORE MONEY AND CONTROL, AND MONEY PLUS CONTROL HELPS ENTRENCH POWER • 1984 WAS THE WARNING • 1776 IS THE RESPONSE • WE ARE NOT YOUR DATA • WE ARE NOT YOUR PATTERN • WE ARE NOT AGAINST AI - JUST THOSE WHO WANT CONTROL • WE ARE FREE ⚠
Bioethics, Blogging, Consumer Data Ownership, Federal Oversight, Pharmaceutical Acquisitions, Predictive Health Systems, Privacy Law, Surveillance Capitalism, Uncategorized Tags:23andMe Acquisition, biotech surveillance, Consumer Genetic Data, Cybersecurity, Data Ethics, DNA Biobank Sale, facts, FTC Privacy Oversight, genetic privacy, Genome Monetization, Medical Algorithm Exploitation, Regeneron Pharmaceuticals, straight forward, truth

Post navigation

Previous Post: KROGER’S DATA CART: How America’s Largest Grocery Chain Turned Loyalty Into Surveillance—and Your Purchases Into Profit
Next Post: HALF A MILLION LIVES, EXPOSED: Two Major Healthcare Breaches Leak Medical, Financial, and Legal Records Across the U.S.

Related Posts

ChatGPT’s Expansion Signals Arrival of the Western “Everything App” AI and Innovation
The Forgotten Web: How America’s Legacy Cables Still Carry Its Secrets Blogging
The Quest for Recognition: Why Some Mock Others Blogging
FBI Warns TeamPCP Cybercriminal Group Is Targeting Software Supply Chains and Cloud Credentials Blogging
Facebook’s Systematic Suppression: Shadow Banning, Algorithmic Throttling, and Engagement Manipulation – Investigation Big Tech
RETAIL UNDER SIEGE: Harrods Joins Growing List of U.K. Retailers Targeted by Cyberattack Attempts Blogging

Leave a Reply Cancel reply

Independent. Unfiltered. Relentless.

Powered by O.R.I.O.N. Network | THRAELYX™

TRJ SYSTEM BOOTING... INITIALIZING SUBSYSTEMS... LINK ESTABLISHED... AWAITING INPUT...
Loading Comments...
%d